BD18

BD18 is a preclinical-stage therapeutic candidate being developed by Biolojic Design for the treatment of autoimmune diseases. As a fully-owned program within Biolojic Design's pipeline, it is developed using the company's proprietary computational platform, which focuses on designing 'multibodies'—computationally engineered antibodies designed to act as logic gates (e.g., binding only in specific microenvironments or requiring dual-target engagement). While specific molecular targets and the exact modality for BD18 have not been publicly disclosed, it is part of a broader portfolio of next-generation antibody therapeutics aimed at modulating the immune system to treat inflammatory and autoimmune conditions.